The controversy surrounding Mylan's EpiPen pricing suggests drugmakers have been slow to adapt to an environment in which millions of Americans must pay thousands of dollars out of pocket before their coverage kicks in.
Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has soared over the past decade. But the drugmaker didn't budge on its price hikes Thursday.
U.S. Sen. Joe Manchin remained mum Wednesday as a pharmaceutical company run by his daughter faced mounting criticism for hiking prices on life-saving allergy injection pens.
The government needs to better protect consumers from high prescription medication costs by setting tougher standards for companies seeking drug exclusivity protection for their brand name products, according to a study.
Sen. Amy Klobuchar, a ranking member of the Antitrust Subcommittee, wants the Federal Trade Commission to investigate the “enormous increase in the price of EpiPens,” following a number of recent media reports regarding the devices' high cost.
Valeant Pharmaceuticals replaced Robert Rosiello as chief financial officer as the embattled company attempts to normalize operations amid a host of ongoing investigations and class action lawsuits.
Pfizer will pay about $14 billion to buy cancer drug developer Medivation in a cash deal aimed at fortifying its hold in one of the hottest and most lucrative areas of medicine.
Wanted: Volunteers willing to be infected with the Zika virus for science. It may sound bizarre, but researchers are planning just such a study—this winter, when mosquitoes aren't biting—to help speed development of much-needed Zika vaccines.
The drug with by far the highest cost, despite the lowest claim count of the 10 most expensive, was Gilead's hepatitis C treatment Sovaldi at more than $3.1 billion. Next were Nexium, which treats gastroesophageal reflux disease, and the cholesterol drug Crestor.
New evidence contradicts a federal panel's recommendations that found the nasal form of the influenza vaccine to be ineffective in fighting the virus. But the differing conclusions may have resulted from the way in which the data were collected.
HHS Secretary Sylvia Mathews Burwell said Thursday she will divert federal funds to support efforts to develop a Zika vaccine.
A blockbuster cancer treatment failed in a key study as the drug's maker, Bristol-Myers Squibb, attempts to extend its usage for lung cancer patients.